Retinal Cholesterol Content is Reduced in Simvastatin-Treated Mice Due to Inhibited Local Biosynthesis Albeit Increased Uptake of Serum Cholesterol

Natalia Mast¹, Ilya R. Bederman², and Irina A. Pikuleva¹

Departments of ¹Ophthalmology and Visual Sciences and ²Pediatrics, Case Western Reserve University,
Cleveland, Ohio
a) Running Title: Statins and the Retina

b) Corresponding author: Dr. Irina A. Pikuleva, Department of Ophthalmology and Visual Sciences, Case Western Reserve University, 2085 Adelbert Rd., Cleveland, OH 44106. Tel: (216)368-3823; fax: (216)368-3171; e-mail: iap8@case.edu

c) 12 text pages
2 tables
8 figures
66 references
248 words in the Abstract
742 words in the Introduction
1484 words in the Discussion

d) Non-standard abbreviations: AMD, age-related macular degeneration; CF, cholesterol and fat-containing diet; DMSO, dimethyl sulfoxide; GC-MS, gas chromatography-mass spectrometry; HMGCR, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; oxLDL, oxidized low density lipoprotein; LDL, low density lipoprotein; LDLR, low density lipoprotein receptor; LC-MS, liquid chromatography-mass spectrometry; PBS, phosphate-buffered saline; RORγ, retinoic acid receptor-related orphan nuclear receptor γ; RPE, retinal pigment epithelium; SREBP2, sterol regulatory element binding protein 2.
Abstract

Statins, a class of cholesterol-lowering drugs, are currently investigated for treatment of age-related macular degeneration, a retinal disease. Herein, retinal and serum concentrations of four statins (atorvastatin, simvastatin, pravastatin, and rosvastatin) were evaluated after mice were given a single drug dose of 60 mg/kg body weight. All statins, except rosvastatin, were detected in the retina: atorvastatin and pravastatin at 1.6 pmols and simvastatin at 4.1 pmols. Serum statin concentrations (pmol/ml) were 223 (simvastatin), 1,401 (atorvastatin), 2,792 (pravastatin), and 9,050 (rosuvastatin). Simvastatin was then administered to mice daily for 6 weeks at 60 mg/kg of body weight dose. Simvastatin treatment reduced serum cholesterol levels by 18% and retinal content of cholesterol, lathosterol but not desmosterol by 24% and 21%, respectively. The relative contributions of retinal cholesterol biosynthesis and retinal uptake of serum cholesterol to total retinal cholesterol input were changed as well. These contributions were 79% and 21%, respectively, in vehicle-treated mice and 69% and 31%, respectively, in simvastatin-treated mice. Thus, simvastatin treatment lowered retinal cholesterol because a compensatory upregulation of retinal uptake of serum cholesterol was not sufficient to overcome the effect of inhibited retinal biosynthesis. Simultaneously, simvastatin-treated mice had a 2.9-fold increase in retinal expression of Cd36, the major receptor clearing oxidized low-density lipoproteins from Bruch's membrane. Notably, simvastatin treatment essentially did not affect brain cholesterol homeostasis. Our results reveal the statin effect on the retinal and brain cholesterol input and are of value for future clinical investigations of statins as potential therapeutics for age-related macular degeneration.
Introduction

Statin drugs inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme in the pathway of cholesterol biosynthesis. HMGCR inhibition reduces intracellular (particularly hepatic) cholesterol and activates sterol regulatory element binding protein 2 (SREBP2), a transcription factor. SREBP2 activation increases the expression of low density lipoprotein receptor (LDLR) on cell surface, thus facilitating an increased uptake of cholesterol-rich low density lipoprotein particles (LDL) from the systemic circulation. The levels of circulating LDL are reduced as are the serum levels of total cholesterol (Brown and Goldstein, 1981).

Statins vary in chemical and pharmacological properties and hence potency, safety, and side effects. Clinical guidelines for prescribing statins were developed based on patient serum lipid-lowering goals (Russell et al., 2018). Statins are administered either as active drugs (atorvastatin, fluvastatin, pitavastatin, pravastatin, and rosuvastatin) or inactive lactone prodrugs (lovastatin and simvastatin), which are hydrolyzed in vivo to their active form chemically or enzymatically by esterases or paraoxonases (Duggan and Vickers, 1990). The active forms of statins share the dihydroxyheptanoic acid functionality and differ in the substitutions on their ring systems (Fig. 1), which define the statin solubility and pharmacokinetic properties. Atorvastatin, fluvastatin, lovastatin, pitavastatin, and simvastatin are lipophilic compounds, whereas pravastatin and rosuvastatin are more hydrophilic (Gazzerro et al., 2012). Lipophilic statins typically enter a cell by passive diffusion, whereas hydrophilic statins are taken up by transporter proteins. Lipophilic statins act at both hepatic and extrahepatic sites, whereas hydrophilic statins are more hepatoselective (Hamelin and Turgeon, 1998). Statins are mainly eliminated via metabolism by cytochrome P450 enzymes (e.g., CYP3A4, CYP2C9, and others), and some of their metabolites represent active drugs as well (Shitara and Sugiyama, 2006). Statin effects are pleiotropic, and in addition to cholesterol lowering, statins improve endothelial function, inhibit inflammatory responses, stabilize atherosclerotic plaques, and modulate platelet function (Calabro and Yeh, 2005).

Statins were originally developed for the management and prevention of cardiovascular and coronary heart diseases. However, statin use may be expanded because currently these drugs are investigated for
treatment of other diseases, including age-related macular degeneration (AMD) (Gehlbach et al., 2009b). AMD damages the retina, the light sensitive tissue lining the back of the eye, and causes irreversible vision loss in the elderly of industrialized countries (Pascolini et al., 2004). The AMD hallmarks include drusen and subretinal drusenoid deposits, lesions with a significant cholesterol content (Curcio et al., 2001; Curcio et al., 2005; Oak et al., 2014). Genetic variants of several cholesterol-related genes (ABCA1, APOE, CETP, LIPC, LPL, LRP6, and VLDLR) are risk factors for AMD (Miller, 2013). Accordingly, statin therapy is tested for decreasing cholesterol content in drusen and subretinal drusenoid deposits and thereby reducing the lesion size or preventing its progression. The anti-inflammatory and anti-angiogenic effects of statins could be beneficial for treatment of AMD as well (Guymer et al., 2013; Vavvas et al., 2016).

Cholesterol is important for normal structure and function of the retina, which maintains cholesterol homeostasis by balancing cholesterol input and output (Fliesler and Bretillon, 2010). Retinal cholesterol input includes local cholesterol biosynthesis and tissue uptake of serum or systemic cholesterol, i.e., cholesterol-containing lipoprotein particles from the systemic circulation (Elner, 2002; Fliesler et al., 1995; Fliesler et al., 1993; Fliesler and Keller, 1995; Tserentsoodol et al., 2006c). Retinal cholesterol output occurs via cholesterol metabolism by cytochrome P450 enzymes 27A1, 46A1, and 11A1 (Pikuleva and Curcio, 2014) as well as removal by lipoprotein particles (Curcio et al., 2011; Fujihara et al., 2014; Tserentsoodol et al., 2006a). Recently, we developed a new methodology and quantified the relative contributions of local and serum cholesterol to the pool of retinal cholesterol in mice (Lin et al., 2016). Local biosynthesis was found to be the major source of retinal cholesterol, accounting for 72% of total retinal cholesterol input. This result suggested that statins have a potential to lower retinal cholesterol but raised the question as to whether statin treatment will lead to a compensatory increase of retinal uptake of serum cholesterol. We addressed this question in the present study by treating mice with simvastatin after we investigated retinal availability for lipophilic (atorvastatin and simvastatin) and hydrophilic (rosuvastatin and pravastin) statins (Gazzarro et al., 2012). These are also high-intensity statins (atorvastatin at 40-80 mg/day and rosvastatin at 20-40 mg/day) and moderate-intensity statins
(simvastatin at 20-40 mg/day and pravastatin at 40-80 mg/day) (Karlson et al., 2016). Studies on the retina were conducted in parallel with those on the brain, whose major source of cholesterol is local biosynthesis because the blood-brain barrier is impermeable to cholesterol.
Materials and Methods

Materials. [25,26,26,26,27,27,27-2H7]cholesterol (D7-cholesterol) was purchased from Cambridge Isotope Laboratories Inc. (Tewksbury, MA), [1,2,5,6-2H4]lathosterol (D5-lathosterol) and [26,26,26,27,27,27-2H6]desmosterol (D6-desmosterol) were from CDN Isotopes (Pointe-Claire, Canada); all statins (atorvastatin, 2-hydroxyatorvastatin, mevastatin, pravastatin, rosuvastatin, N-desmetylrosuvastatin, simvastatin, and simvastatin hydroxy acid) were from Toronto Research Chemicals Inc. (Toronto, Canada). All other chemicals including deuterated water (D2O) were from Sigma-Aldrich (St. Lois, MO). Powdered regular rodent chow (5P76 Prolab Isopro RMH 3000) was from T.R. Last Co. (Saxonburg, PA) and contained 0.02% cholesterol (w/w) and 5.0% fat (w/w). This chow was used to prepare two custom diets with increased cholesterol and fat content: CF, which had 0.3% unlabeled cholesterol (w/w) and 15% fat (w/w), and D7-CF, which had 0.3% D7-cholesterol (w/w) and 15% fat (w/w). These diets were prepared as described (Lin et al., 2016). Briefly, 0.3 g of cholesterol or D7-cholesterol was stirred into 9.7 g of peanut oil until cholesterol was dissolved. Cholesterol solution and 35 ml of water were then added sequentially to 90 g of powdered chow, followed by thorough component mixing for 30 min until a homogeneous dough was formed. This dough was used for the manual preparation of pellets, which were dried at 37°C overnight.

Animals. C57BL/6J female mice (3-4 months old) were obtained from the Jackson Laboratory and housed in the Animal Resource Center at Case Western Reserve University. Animals were kept on a 12-hour light-dark cycle and provided food and water ad libitum. All animal experiments were in compliance with the Guide for Care and Use of Laboratory Animals by the National Institutes of Health and were approved by Case Western Reserve University’s Animal Care and Use Committee. Female and male mice have similar levels of serum and retinal sterols and show the same pattern of sterol changes in response to drug treatment (El-Darzi et al., 2018). Yet, female mice typically have higher data variability due to monthly hormonal fluctuations. Therefore, female mice were used to ensure that the observed effects indeed take place, despite higher data variability.
**Single Dose Statin Administration.** Simvastatin, atorvastatin, rosuvastatin, and pravastatin were given by oral gavage (n=6 mice per statin) at 60 mg/kg body weight dose from 10 mg/ml solutions. Simvastatin was formulated with aqueous 2% dimethyl sulfoxide (DMSO), 30% PEG 400, and 5% Tween 80. Atorvastatin was dissolved in DMSO and then added to castor oil yielding a 5% DMSO and 95% castor oil solution. Rosuvastatin was in aqueous 4% DMSO and 30% PEG 400. Pravastatin was dissolved in phosphate-buffered saline (PBS). Two hours after gavage, mice were deeply anesthetized by intraperitoneal injections of a ketamine (80 mg/kg) and xylazine (15 mg/kg) cocktail. Blood was collected by cardiac puncture, and serum was prepared as described (Mast et al., 2010). Three of six mice from each statin group were then perfused through the heart with 30 ml PBS using a peristaltic pump at the flow rate of ~1 ml/min to eliminate residual blood (if any) from tissues; the remaining three animals were left non-perfused.

**Simvastatin Administration for Cholesterol Input Measurements.** The experimental paradigms are shown in Fig. 2. In all experiments, the treatment time was 6 weeks, and simvastatin (60 mg/kg body weight) or vehicle (0.2-0.25 ml of aqueous 2% DMSO, 30% PEG 400, and 5% Tween 80 solution) were given daily by oral gavage. At the end of treatment, mice were fasted overnight and anesthetized the next morning 1 hr after the simvastatin or vehicle administration. Blood was collected, and mice were perfused through the heart with 30 ml of PBS. Subsequent tissue isolation was as described for the serum (Mast et al., 2010), retina (Saadane et al., 2014), and brain (Lin et al., 2016).

**Effect of Simvastatin on Steady-State Tissue Cholesterol.** Mice were put on CF diet for 2 weeks and then on simvastatin or vehicle for 6 weeks while remaining on the same diet and drinking normal water (Fig. 2A).

**Effect of Simvastatin on Tissue Uptake of Dietary Cholesterol.** This experiment (Fig. 2B) was similar to that in Fig. 2A, except that unlabeled cholesterol in the CF diet during the last two weeks of simvastatin treatment was replaced with the same amount of D7-cholesterol.

**Effect of Simvastatin on Tissue 2H Cholesterol Enrichment.** The experimental design (Fig. 2C) was similar to that in Fig. 2A, except that drinking water during the last two weeks of simvastatin
treatment contained $^2$H (6% final). Prior to switching to 6% D$_2$O, animals were injected intraperitoneally with 0.5-0.8 ml of 100% D$_2$O to enrich body water to 3.5% deuterium.

**Statin Quantifications.** One retina, 50 µl of serum or 2 mg of brain protein homogenate were mixed with 1.5 ml of acetonitrile and homogenized by 20 passages through 21G needle (retina and brain) or vortexing the solution (serum). Mevastatin was added as an internal standard (2 pmol per retina, 1 pmol/mg of brain protein, and 10 pmol per 50 µl of serum). Homogenized samples were subjected to centrifugation at 3,000 g for 15 min at room temperature, and the supernatants obtained were isolated and dried in a Savant SpeedVac concentrator (Thermo Fisher, Waltham, MA). Dry residues were dissolved in 50 µl of acetonitrile, and 30 µl of this solution was used for liquid chromatography-mass spectrometry (LC-MS).

**LC-MS/MS Instrumentation and Conditions.** LC analyses were performed using a Dionex UltiMate 3000 system (Thermo Fisher Scientific Inc., Rockford, IL) equipped with a binary pump, an on-line degasser, an auto-sampler, and a column temperature controller. The chromatographic separations were performed on a Gemini C18 column (4.6 × 250 mm, 5 µm; Phenomenex, Torrance, CA) at a flow rate of 500 µL/min with the temperature maintained at 30°C. Mobile phase A was water containing 0.1% formic acid (v/v) and mobile phase B was 100% methanol containing 0.1% formic acid (v/v). Samples were subjected to gradient elution. At 0-5 min, the eluent consisted of mobile phase A and mobile phase B (50:50, v/v); at 5-20 min, the eluent was changed to mobile phase B (100%), and at 20-22 min, the eluent was changed back to mobile phase A and mobile phase B (50:50, v/v). Subsequent mass spectrometry detection was with a TSQ Quantum Ultra AM triple quadrupole mass spectrometer (Thermo Fisher Scientific Inc., Rockford, IL), equipped with a heated electrospray ionization source operating in the positive ionization mode. The ion source parameters were as follows: spray voltage of 3000 V; sheath gas pressure (N2) of 60 psi; auxiliary gas pressure (N2) of 20 psi; ion transfer tube temperature of 275°C; collision gas (Ar) of 1.5 mTorr; collision activation dissociation of 6.0 psi; Q1/Q3 peak resolution of 0.7 Da; and scan width of 0.002 Da. The samples were analyzed via selective reaction monitoring with the precursor → product ion transitions of $m/z$ 559.2 → 440 for atorvastatin, 575.2 → 466 for 2-
hydroxyatorvastatin, 419.2 → 285.0 for simvastatin, 437.2 → 303.0 for simvastatin hydroxy acid, and 391.2 → 271.2 for mevasstatin. Selected ion monitoring was used for analyses of pravastatin (m/z 447.2), rosvastatin (m/z 482.1), and N-desmethylosuvastatin (m/z 468.1). The dwell time set was 400 ms for all the analytes. Quantification of the statins was based on the ratio of the peak area of the analyte to the internal standard. All data collected were acquired in the centroid mode and processed using Xcalibur 2.2 software (Thermo Fisher Scientific Inc., Rockford, IL).

**Sterol Quantifications.** Tissue homogenates (10%) were prepared in 50 mM potassium phosphate buffer (pH 7.2) containing 300 mM sucrose, 0.5 mM dithiothreitol, 10 mM EDTA, 100 µg/ml butylhydroxytoluene, and a cocktail of protease inhibitors (Applied Biosystems, Foster City, CA). Cellular debris were removed by centrifugation at 1500 g for 15 min, and protein concentration of the supernatant was determined by BCA Protein Assay Kit (Thermo Fisher Scientific Inc., Rockford, IL) (Lin et al., 2016). D7-cholesterol was added as an internal standard at 60 nmol per 50 µl of serum, 200 nmol per mg of brain protein, and 10 nmol per one retina; the concentrations (per retina) of D7-lathosterol and D6-desmosterol were 100 pmol. Lipids were extracted by Folch, saponified, derivatized with 100 µl of bis-(trimethylsilyl) trifluoroacetamide/trimethylchlorosilane, and analyzed by gas chromatography-mass spectrometry (GC-MS) as described (Mast et al., 2011).

**Tissue Uptake of Dietary Cholesterol.** Tissue appearance of D7-cholesterol in mice after 2 weeks on D7-CF diet (Fig. 2B) was measured by monitoring the ion fragment with m/z value of 375 and was presented as the percentage from the sum of tissue unlabeled and D7-cholesterol (Lin et al., 2016).

**Body Water 2H Enrichment in Individual Animals.** Serum of mice which received D2O (Fig. 2C) was collected after animal euthanasia and measured for isotopic exchange with acetone as described (Lin et al., 2016).

**Tissue 3H Cholesterol Enrichment.** The cholesterol ion fragments with m/z values from 368 to 373 were monitored (Lin et al., 2016) and corrected for the natural abundance of cholesterol mass isotopomers (Lee et al., 1994). The data obtained were then divided by: i) 22, the maximum number of deuterium
atoms that can be incorporated into cholesterol (Jones et al., 1993); and ii) the body water $^2$H enrichment of an individual animal. Since mice were on D$_2$O for two weeks (Fig. 2C), tissue $^2$H cholesterol enrichment reflected the fraction of cholesterol (%), which was synthesized over a 2-week period. This fraction represented the sum of local and whole body cholesterol biosynthesis with the latter mainly reflecting tissue uptake of blood-borne cholesterol.

**Calculations of Rates for Tissue Cholesterol Uptake and Local Biosynthesis.** The calculations were the same as described (Lin et al., 2016) and used the following equations:

\[
\text{Tissue cholesterol uptake per 2 weeks, } \% = \frac{\text{D}_7\text{-cholesterol in tissue, } \%}{\text{D}_7\text{-cholesterol in serum, } \%} \times 100 \quad \text{eq. 1}
\]

\[
\text{Tissue } ^2\text{H cholesterol enrichment from uptake per 2 weeks, } \% = \frac{\left( \frac{\text{uptake per 2 weeks, } \% \times ^2\text{H enrichment of serum cholesterol, } \%}{100} \right)}{\text{uptake per 2 weeks, } \%} \quad \text{eq. 2}
\]

\[
\text{Biosynthesis per 2 weeks, } \% = \frac{\text{total } ^2\text{H cholesterol enrichment in organ, } \% - \left( \frac{\text{uptake per 2 weeks, } \% \times ^2\text{H enrichment of serum cholesterol, } \%}{100} \right)}{\text{uptake per 2 weeks, } \%} \quad \text{eq. 3}
\]

\[
\text{Rate of total cholesterol input, } \mu\text{g/day/g wet tissue} = \frac{\text{cholesterol content, } \mu\text{g/g wet tissue} \times \left( \frac{\text{uptake per 2 weeks, } \% + \text{biosynthesis per 2 weeks, } \%}{100/14} \right)}{100/14} \quad \text{eq. 4}
\]

\[
\text{Rate of local tissue cholesterol biosynthesis, } \mu\text{g/day/g wet tissue} = \frac{\text{cholesterol content, } \mu\text{g/g wet tissue} \times \text{tissue biosynthesis per 2 weeks, } \%}{100/14} \quad \text{eq. 5}
\]

\[
\text{Rate of tissue cholesterol uptake, } \mu\text{g/day/g wet tissue} = \frac{\text{cholesterol content, } \mu\text{g/g wet tissue} \times \text{tissue uptake per 2 weeks, } \%}{100/14} \quad \text{eq. 6}
\]

\[
\text{Tissue cholesterol turnover, days} = \frac{\text{cholesterol content, } \mu\text{g/g wet tissue}}{\text{input, } \mu\text{g/day/g wet tissue}} \quad \text{eq. 7}
\]

**Quantitative Real Time PCR (qRT-PCR).** Total RNA (1 µg) from pooled retinal samples was isolated as described (Zheng et al., 2015) using the TRIzol Reagent (Life Technologies, Grand Island, NY). Total RNA was then converted to cDNA by SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. PCR reactions (performed in triplicates) were carried out using 2 µl of cDNA, a pair of gene-specific primers (Table 1), and a FastStart Universal SYBR Green Master (Rox) (Roche Life Science, Indianapolis, IN) as specified by the manufacturer. The reaction volume was 25 µl, and the final concentration of the primers was 1 µM. Gene expression was
normalized to the expression of GAPDH. Changes in relative mRNA level were calculated by the $2^{-\Delta \Delta Ct}$ method (Pfaffl, 2001).

**Statistics.** All data represent the means ± SD of the measurements in individual mice; the number of animals (n) is indicated in each figure. Data were analyzed by a two-tailed, unpaired Student's t-test using GraphPad Prism software (La Jolla, CA). Statistical significance was defined as *, $P \leq 0.05$; **, $P \leq 0.01$; ***, $P \leq 0.001$. 
Results

Serum Statin Concentrations after a Single Dose Administration. Seven compounds were analyzed: four statins (atorvastatin, simvastatin, pravastatin, and rosvastatin) and three statin derivatives: 2-hydroxyatorvastatin, an active atorvastatin metabolite (Christians et al., 1998); simvastatin hydroxyacid, the active form of simvastatin (Prueksaritanont et al., 1997); and N-desmethylrosuvastatin, the active rosvastatin metabolite (Martin et al., 2003). All compounds, except N-desmethylrosuvastatin, were detected in mouse serum 2 hrs after oral administration (Fig. 3A). The concentrations of rosvastatin and pravastatin were the highest (9,050 and 2,792 pmol/ml, respectively) and those of simvastatin and simvastatin hydroxyacid were the lowest (223 and 206 pmol/ml, respectively). The concentrations of atorvastatin and 2-hydroxyatorvastatin were 1,401 and 1,765 pmol/ml, respectively. Undetectable levels of N-desmethylrosuvastatin were consistent with in vivo data documenting that metabolism is a minor route of rosvastatin clearance (Martin et al., 2003).

Retinal Statin Concentrations after a Single Dose Administration. The retinas of both perfused and non-perfused mice were used to detect four statins (atorvastatin, simvastatin, pravastatin, and rosvastatin) and three statin metabolites (2-hydroxyatorvastatin, simvastatin hydroxyacid, N-desmethylrosuvastatin). (Fig. 3B). Only atorvastatin, simvastatin, and pravastatin were detected in all retinas; simvastatin hydroxyacid was also present in non-perfused retinas. Retinal statin concentrations in the perfused retinas were within the same order of magnitude: 1.6 pmol/retina for atorvastatin and pravastatin, and 4.1 pmol/retina for simvastatin. Mouse perfusion generally reduced retinal statin concentrations. However, this reduction varied among the statins (47% for atorvastatin, 14% for simvastatin, and 6% for pravastatin), thus suggesting that some of the statins could be partially washed out from the retina during the perfusion. Remarkably, rosvastatin, the most abundant statin in the serum (Fig. 3B), was not detected in the retina (< 0.1 pmol is the detection limit), an indication that retinal contamination with blood was only minimal in our preparations. Of all the detected statins, simvastatin concentrations were the lowest in the serum but the highest in the retina, even in the perfused retinas. This
finding suggested that simvastatin is more available to the retina than other statins and served as a justification for simvastatin use for our subsequent long-term treatment.

**Serum and Retinal Simvastatin Content after the Six-Week Statin Administration.** Serum levels of simvastatin and simvastatin hydroxyacid were similar to those after a single dose statin administration and equal to 224 pmol/ml and 195 pmol/ml, respectively (Fig. 4A). Yet, the retinal content of simvastatin (all mice were perfused for these quantifications) was higher (5.2 pmol/retina), and simvastatin hydroxyacid was also detected (1.3 pmol/retina, Fig. 4B).

**Serum and Retinal Cholesterol Content after the Six-Week Simvastatin Administration.** Simvastatin treatment reduced serum and retinal cholesterol levels by 18% and 24%, respectively (Fig. 5A,B), and thereby justified subsequent studies of the simvastatin effect on retinal cholesterol input following retinal quantifications of cholesterol precursors.

**Retinal Levels of Cholesterol Precursors after the Six-Week Simvastatin Administration.** Four cholesterol precursors were measured (Fig. 5B) including lathosterol and desmosterol as potential markers of cholesterol biosynthesis in retinal neurons and astrocytes, respectively. This is by analogy with the brain, where the lathosterol and desmosterol levels reflect cholesterol biosynthesis in neurons and astrocytes, respectively (Pfrieger and Ungerer, 2011). The levels of lathosterol, lanosterol, and zymosterol were decreased in simvastatin-treated mice by 21%, 22%, and 52%, respectively, whereas the desmosterol levels remained unchanged.

**Retinal Cholesterol Input after the Six-Week Simvastatin Administration.** In vehicle- and simvastatin-treated mice on normal water and D_{7}-CF diet (Fig. 2B), the two-week retinal uptake of dietary D_{7}-cholesterol was 1.5% and 1.8%, respectively (Fig. 6B, Table 2, line 3). The serum of these mice contained 37% (vehicle-treated) and 47% (simvastatin-treated) of dietary D_{7}-cholesterol (Fig. 6A, Table 2, line 3). Equation 1 (see Methods) was used to calculate total retinal uptake of cholesterol from the systemic circulation (3.8% for both vehicle- and simvastatin-treated mice, Table 2, line 4).

In vehicle- and simvastatin-treated mice on D_{2}O and CF diet (Fig. 2C), the two-week retinal {\textsuperscript{2}}H cholesterol enrichment was 16% and 9%, respectively (Fig. 7B, Table 2, line 5). In the serum, these
values were 16% and 12%, respectively (Fig. 7A, Table 2, line 5). Equation 2 was used to calculate retinal $^2$H cholesterol enrichment from the tissue uptake of blood-borne $^2$H cholesterol (0.7% and 0.5% in vehicle- and simvastatin-treated mice, respectively, Table 2, line 6). Then, equation 3 was used to calculate fractional retinal cholesterol biosynthesis (15.3% and 8.5% of cholesterol in vehicle- and simvastatin-treated mice, respectively, Table 2, line 7).

To determine the absolute rates of retinal cholesterol input per day, retinal cholesterol content (Table 2, line 2) and equations 4-6 were used. In vehicle-treated mice, the rate of total retinal cholesterol input (per day per gram of wet tissue) was 35.7 µg, of which 28.2 µg of cholesterol were provided by local biosynthesis and 7.5 µg of cholesterol were uptaken from the systemic circulation. In simvastatin-treated mice, these values (µg of cholesterol/day/g of wet tissue) were 17.2, 11.9, and 5.3, respectively, Table 2, lines 8-10). Thus, total retinal cholesterol input was decreased in simvastatin-treated mice as was the ratio of local retinal biosynthesis to tissue uptake of systemic cholesterol ($28.2/7.5=3.8$ in vehicle-treated mice vs $11.9/5.3=2.2$ in simvastatin-treated mice). These data indicate mouse treatment with simvastatin inhibited retinal cholesterol biosynthesis but elicited a compensatory upregulation of cholesterol uptake from the systemic circulation. Yet, this increased uptake was not sufficient to compensate for the inhibition of retinal cholesterol biosynthesis; therefore, retinal cholesterol levels were decreased in simvastatin-treated mice. Retinal cholesterol turnover rates were also calculated using retinal cholesterol content (Table 2, line 2) and equation 7. These rates were 72 and 113 days in vehicle- and simvastatin-treated mice, respectively, Table 2, line 11). Thus, simvastatin treatment decreased the rate of retinal cholesterol turnover, probably because of the inhibition of retinal cholesterol biosynthesis.

**Retinal Expression of the Cholesterol Input Genes.** Only four genes were quantified: *Srebap2, Ldlr, Cd36*, and *Scarb1* (former *Sr-bI*) (Fig. 8). *Srebap2* encodes a transcription factor, which controls tissue cholesterol biosynthesis. *Ldlr* encodes the receptor for LDL, which uptakes systemic cholesterol and is controlled by *Srebap2* (Horton et al., 2002). *Cd36* and *Scarb1* are the class B scavenger receptors responsible for uptake of multiple ligands including fatty acids and oxidized low density lipoprotein (oxLDL, CD36) or free cholesterol and cholesterol esters from high-density lipoproteins (SCARBI)
LDLR, CD36, and SCARBI were all previously shown to be present on the retinal pigment epithelium (RPE) basolateral side (Duncan et al., 2009; Houssier et al., 2008; Tserentsoodol et al., 2006b), and therefore could mediate the increased retinal uptake of systemic cholesterol in simvastatin-treated mice. The expression of Srebp2 was decreased 1.25-fold in simvastatin-treated mice, consistent with the role of this transcription factor as a cholesterol sensor (Horton et al., 2002), yet the expression of Ldlr, the SREBP2 target, remained unchanged. Retinal levels of Cd36 were increased 2.9-fold in simvastatin-treated mice as compared to vehicle-treated animals, whereas the levels of Scarb1 were similar in vehicle- and simvastatin-treated mice.

**Brain Simvastatin Concentration and Cholesterol Input in Vehicle- and Simvastatin-Treated Mice.** Similar to the retina, simvastatin was detected in the brain (Fig. 4C) but at a much lower level than that in the retina (0.013 vs 2.17 pmol/mg protein, assuming that the average mouse retina weighs ~ 2.4 mg). Unlike the retina, simvastatin hydroxyacid was not detected in the brain, either because it was washed out during brain perfusion or it was not formed in the brain. Simvastatin treatment did not lead to statistically significant changes in brain cholesterol concentrations (Fig. 5C), the two-week retinal uptake of dietary D7-cholesterol (Fig. 6C), and the two-week retinal 2H cholesterol enrichment (Fig. 7C). Accordingly, the calculated rates of brain cholesterol biosynthesis and uptake from the systemic circulation were similar in simvastatin- and vehicle-treated mice as were the ratios of local brain biosynthesis to tissue uptake of brain cholesterol (Table 2, lines 9 and 10). Thus, simvastatin had only very minor effect on the brain cholesterol input.
Discussion

The present work led to three major findings. First, atorvastatin, simvastatin, and pravastatin cross the blood-retina barrier. Second, simvastatin treatment reduces retinal cholesterol by inhibiting retinal cholesterol biosynthesis, yet upregulating retinal uptake of systemic cholesterol. Third, lathosterol could be a marker of cholesterol biosynthesis in the retina.

Until the present study, it was not clear whether atorvastatin or simvastatin can cross the blood-retina barrier, which separates the retina from the systemic circulation. We detected simvastatin and atorvastatin in the retina of perfused mice after a single oral dose, and thereby showed that the blood-retinal barrier is permeable (or partially permeable) to atorvastatin and simvastatin (Fig. 3B). Additionally, simvastatin hydroxyacid (the active form of simvastatin) was found in the perfused retina after the 6-week simvastatin administration at a simvastatin to simvastatin hydroxyacid ratio of 4.3 to 1. However, in the serum, this ratio was equimolar (Fig. 4A,B) suggesting that either less simvastatin hydroxyacid than simvastatin reached the retina from the systemic circulation or less simvastatin was hydrolyzed in the retina than in the liver. A third possibility is that mouse perfusion washed out more simvastatin hydroxyacid from the retina than simvastatin.

Pravastatin is more hydrophilic than atorvastatin and simvastatin and is known to be mainly distributed to the liver and kidney, where it is taken up by tissue-specific transporters (Shitara and Sugiyama, 2006). Recently, pravastatin transporters were found in the inner and outer blood-retinal barriers (Akanuma et al., 2013; Hosoya et al., 2009), and pravastatin was shown to be transported across the blood-retina barriers in both directions (Fujii et al., 2015). Moreover, systemically administered pravastatin was reported to reduce signs of diabetic retinopathy in a clinical trial (Gordon et al., 1991) and to better preserve the appearance of the retina in hypercholesterolemic rabbits (Fernandez-Navarro et al., 2016). Thus, retinal detection of pravastatin (Fig. 3B) is consistent with literature data. At the equivalent dose, pravastatin has a lower potency as compared to simvastatin and atorvastatin (Jones et al., 2003). However, risks of adverse events increase with statins potency (per milligram), and relative to rosvastatin (if to take these risks as 100%) are 7.5% (lovastatin), 17% (pravastatin), 26% (simvastatin),
and 55% (atorvastatin) (Hoffman et al., 2012). Hence, in future studies of statins as anti-AMD therapeutics, pravastatin could be an alternative to atorvastatin or simvastatin in case of an adverse event, and atorvastatin or simvastatin need to be discontinued.

Mice and humans have differences in retinal structure and physiology (Fliesler, 2015) and the way the two species handle cholesterol (Pikuleva and Curcio, 2014). These differences include a lack of macula in mice and the major lipoprotein particles that carry cholesterol in the systemic circulation (HDL in mice and LDL in humans). Thus, local cholesterol biosynthesis may not be the major source of retinal cholesterol in human retina like it is in mouse retina. However, we know that similar to mice (Zheng et al., 2015), systemic cholesterol has very little effect on retinal cholesterol in primates. For example, in monkeys fed an atherogenic diet, the plasma cholesterol was increased >7-fold, whereas retinal cholesterol remained unchanged (Hyman et al., 1981). Also, there is no consistent association between serum lipids or lipid pathway genes and the incidence or progression of AMD (Klein et al., 2014). If the uptake of systemic cholesterol was the major source of cholesterol for human retina, this association would exist and be strong. Furthermore, despite HDL being the major carrier of cholesterol in rat serum, both monkey and rat retinas (namely RPE) were shown to avidly uptake systemic cholesterol carried by LDL (Elner, 2002; Tserentsoodol et al., 2006b). Finally, significant amounts of 7- and 8-dehydrocholesterol, biosynthetic cholesterol precursors, were found in the retina of the spontaneously aborted fetuses with genetic defect in cholesterol biosynthesis (Atchaneeyasakul et al., 1998). If local cholesterol biosynthesis did not contribute significantly to a pool of total retinal cholesterol in humans, 7- and 8-dehydrocholesterol would not be detected in the retina of these subjects. Thus, evidence from different type of studies suggest that in humans, like in mice, local cholesterol biosynthesis is a quantitatively important source of cholesterol for the retina. If so, the major findings of the present work may be of human relevance.

Retinal uptake of cholesterol from the systemic circulation was increased 1.5-fold in simvastatin-treated mice as compared to vehicle-treated animals (31% vs 21% of total retinal cholesterol input, respectively, Table 2, line 10). Simultaneously, simvastatin-treated mice had almost a 3-fold increase in
retinal expression of Cd36, the principal receptor for oxLDL (Fig. 8). The mechanism for this increase is currently unclear but could involve the retinoic acid receptor-related orphan nuclear receptor γ (RORγ), a transcription factor. The Cd36 expression seems to negatively correlate with RORγ activation in non-retinal tissues (Raichur et al., 2007; Urlep et al., 2017), and specific cholesterol precursors downstream of lanosterol could be the RORγ activating ligands (Hu et al., 2015; Santori et al., 2015). We quantified retinal lanosterol and two potential RORγ ligands (zymosterol and desmosterol) and showed that the levels of lanosterol, zymosterol but not desmosterol were decreased in simvastatin-treated mice (Fig. 5B). Thus, a decrease in zymosterol levels supports the RORγ involvement in the Cd36 increase. Also, simvastatin effect on Cd36 is consistent with the receptor expression pattern (on both RPE sides, microvascular endothelial cells, and macrophages) and available literature data (Houssier et al., 2008; Picard et al., 2010; Ryeom et al., 1996). Cd36 deficiency in mice leads to multiple manifestations including the sub-RPE accumulation of oxLDL (Houssier et al., 2008; Picard et al., 2010). Similarly, oxLDL is detected sub-RPE in AMD (Kamei et al., 2007; Yamada et al., 2008). Remarkably, an expression-increasing polymorphism of CD36 was found to be protective against AMD in a clinical study (Kondo et al., 2009), and the pharmacological CD36 stimulation in Apoe−/− mice on a high fat high cholesterol diet reduced the oxLDL accumulation (Picard et al., 2010).

Retrospective investigations of statin therapy and AMD produced inconsistent results (Gehlbach et al., 2009a; Tsao and Fong, 2013). Yet, in the two recent prospective trials of simvastatin and atorvastatin (Guymer et al., 2013; Vavvas et al., 2016), there was a clear statin effect on AMD in a subset of patients. In the simvastatin trial (40 mg/day for 3 years), which reduced the risk of progression from intermediate to advanced AMD by ~5-fold, this subset was the patients with the CC variant (Y402H) of the complement factor H (Guymer et al., 2013). In the atorvastatin trial (80 mg/day for 1 year), led to drusen regression and visual gain (+3.3 letters) in 10 of 23 patients, the specific features of the responders were not identified (Vavvas et al., 2016). Our data raise a possibility that the polymorphism in CD36 may determine, at least in part, responsiveness to atorvastatin treatment. Indeed, the levels of plasma oxLDL
increase with age (Cicero et al., 2013), and oxLDL can incite an inflammatory response in Bruch's membrane, a structure below the RPE (Handa et al., 2017). Conceivably, patients that responded to the atorvastatin treatment (Vavvas et al., 2016) could have less oxLDL in Bruch's membrane due to the CD36 polymorphism that decreases the Bruch's membrane oxLDL levels. Similarly, the CD36 polymorphism/CC complement factor H carriers in the simvastatin trial (Guymer et al., 2013) could be better responders to the treatment as a smaller amount of oxLDL in their Bruch's membrane will cause a smaller impact on their complement system, which is already dysregulated. A caveat to this explanation is that some animal studies consider the RPE uptake of oxLDL a protective event (Picard et al., 2010), whereas other studies suggest that this uptake could elicit negative consequences (Hoppe et al., 2001; Yamada et al., 2008).

In the brain, neurons and astrocytes have different predominant pathways of cholesterol biosynthesis, the Kandutsch-Russell and Bloch pathways, respectively, with lathosterol being a cholesterol precursor and the marker of cholesterol biosynthesis in the Kandutsch-Russell pathway, and desmosterol being an intermediate and the marker of cholesterol biosynthesis in the Bloch pathway (Pfrieger and Ungerer, 2011). By using a complex approach including separate administrations of deuterated water and deuterated dietary cholesterol to mice, we showed that simvastatin treatment inhibited cholesterol biosynthesis in the retina (Table 2). In parallel, by using a simpler approach, i.e. tissue sterol quantifications by GC-MS, we documented a decrease in the retinal lathosterol but not desmosterol levels in simvastatin-treated mice (Fig. 5B). Hence, the levels of retinal lathosterol could reflect cholesterol biosynthesis in the retina and specifically retinal neurons and be a marker of simvastatin effect.

In summary, we documented that atorvastatin, simvastatin, and pravastatin can cross the blood-retinal barrier. We showed that simvastatin treatment lowered retinal but not brain cholesterol and inhibited retinal cholesterol biosynthesis while upregulating retinal uptake of systemic cholesterol. The latter possibly occurred via the upregulation of Cd36, encoding a major receptor for oxLDL. Our results provide mechanic insight into the statin effect on the retina and are of value for future clinical studies investigating statins as potential therapeutics for AMD.
Acknowledgements

The authors thank Yong Li for technical assistance, Joseph B. Lin and Dr. Marcin Golczak for initial studies, and the Visual Sciences Research Center Core Facilities for help with mouse maintenance (Heather Butler and Kathryn Franke).
Author Contributions

Participated in research design: Mast and Pikuleva.

Conducted experiments: Mast and Bederman.

Performed data analysis: Mast, Bederman, and Pikuleva.

Wrote the manuscript: Pikuleva.
References


Footnotes

This work was supported in part by the National Institutes of Health National Eye Institute [Grants EY018383 and EY011373]. I.A.P. is a Carl F. Asseff Professor of Ophthalmology.
**Figure Legends**

**Fig. 1.** Chemical structures of statins and statin metabolites investigated in the present work. The dihydroxyheptanoic acid functionality is highlighted in grey.

**Fig. 2.** Experimental paradigms for the measurements of: (A), tissue steady-state cholesterol levels; (B) tissue uptake of dietary cholesterol; and (C) tissue cholesterol input comprised of local cholesterol biosynthesis and tissue uptake of the synthesized cholesterol from the systemic circulation. The number of animals (n) for each experiment is indicated in parenthesis. CF, rodent chow containing 0.3% cholesterol and 10% peanut oil; D\textsubscript{7}-CF, rodent chow containing 0.3% deuterated cholesterol and 10% peanut oil; D\textsubscript{2}O, deuterated water.

**Fig. 3.** Quantifications of different statins in mouse serum (A) and retina (B) after a single dose (60 mg/kg body weight) drug administration by oral gavage (n=3 mice or 6 eyes per statin). np and p, the retinas of non-perfused and perfused mice, respectively; ATR, atorvastatin; 2-HATR, 2-hydroxyatorvastatin, SIM, simvastatin; SHA, simvastatin hydroxyacid; PRV, pravastatin; ROS, rosuvastatin; N-DROS, N-desmethyl rosuvastatin; ND, non-detectable (the limit of drug detection is 0.1 pmol per retina or 20 pmol/ml serum). All data represent the means ± SD of the measurements in individual mice.

**Fig. 4.** Quantifications of simvastatin (SIM) and simvastatin hydroxyacid (SHA) in the serum (A), retina (B), and brain (C) of mice after the six-week simvastatin administration (60 mg/kg body weight/day) by oral gavage (n=3 mice or 6 eyes per statin). SIM, simvastatin; SHA, simvastatin hydroxyacid; ND, non-detectable (the limit of drug detection is 20 pmol/ml of serum, 0.1 pmol per retina, and 0.05 pmol/mg of brain protein). All data represent the means ± SD of the measurements in individual mice.
Fig. 5. Sterol quantifications in the serum (A), retina (B), and brain (C) of mice after the six-week simvastatin administration (60 mg/kg body weight/day) by oral gavage (n=6 mice per each treatment group). Veh, vehicle-treated mice, SIM, simvastatin-treated mice. All data represent the means ± SD of the measurements in individual mice. Asterisks are statistically significant changes relative to the vehicle-treated group as assessed by a two-tailed, unpaired Student’s t-test. *P ≤ 0.05, and **P ≤ 0.01.

Fig. 6. Relative tissue enrichment with D<sub>7</sub>-cholesterol in the serum (A), retina (B), and brain (C) of mice fed for two weeks with rodent chow containing 0.3% D<sub>7</sub>-cholesterol and 10% peanut oil (Fig. 2B). All data represent the means ± SD of the measurements in individual mice. Asterisks are statistically significant changes relative to the vehicle-treated group as assessed by a two-tailed, unpaired Student’s t-test. **P ≤ 0.01, ***P ≤ 0.001.

Fig. 7. Relative tissue cholesterol enrichment with <sup>2</sup>H in the serum (A), retina (B), and brain (C) of mice maintained for two weeks on 6% D<sub>2</sub>O (Fig. 2C). All data represent the means ± SD of the measurements in individual mice. Asterisks are statistically significant changes relative to the vehicle-treated group as assessed by a two-tailed, unpaired Student’s t-test. ***P ≤ 0.001.

Fig. 8. Retinal gene expression in mice after the six-week simvastatin administration (60 mg/kg body weight/day) by oral gavage. All data represent the means ± SD of triplicate measurements on a pooled sample of individual retinas from 5 mice. Since the error bars represent the technical variability of the measurements, statistical significance of changes in the gene expression could not be assessed.
Table 1. Primer sequences for quantitative real-time PCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer (5' to 3')</th>
<th>Reverse primer (5' to 3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cd36</td>
<td>TACAGAAGACCTGGGCTTGG</td>
<td>GAGAGGCGGCGATAGTATCA</td>
</tr>
<tr>
<td>Gapdh</td>
<td>AGTCCATGCCATCACTGCCACC</td>
<td>CCAGTGAGCTTCCCGTTCAAGC</td>
</tr>
<tr>
<td>Ldr</td>
<td>ACCTGCCGACCTGATGAATTC</td>
<td>GCAGTCATGTTACGGTCACA</td>
</tr>
<tr>
<td>Scarb1</td>
<td>TTGGCCTTTTTGTTGGGATG</td>
<td>ATCGATCTTGCTGAGTCCGT</td>
</tr>
<tr>
<td>Srebp2</td>
<td>ATGATCACCGCCGACGTTCA</td>
<td>GGTCGCTCGTCCGTTGTATATC</td>
</tr>
</tbody>
</table>
Table 2. Calculations for tissue cholesterol biosynthesis and uptake rates.

<table>
<thead>
<tr>
<th>Line</th>
<th>Parameter</th>
<th>Serum</th>
<th>Retina</th>
<th>Brain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>VEH</td>
<td>SIM</td>
<td>VEH</td>
</tr>
<tr>
<td>#</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Cholesterol content: mg/dL, serum; nmol/mg protein, retina and brain</td>
<td>163</td>
<td>132</td>
<td>64.4</td>
</tr>
<tr>
<td>2</td>
<td>Cholesterol content, μg/g wet tissue</td>
<td>2,576</td>
<td>1,952</td>
<td>12,163</td>
</tr>
</tbody>
</table>

**Treatment with Dietary D<sub>7</sub>-Cholesterol**

<table>
<thead>
<tr>
<th>Line</th>
<th>Parameter</th>
<th>Serum</th>
<th>Retina</th>
<th>Brain</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>D&lt;sub&gt;7&lt;/sub&gt;-cholesterol appearance, 2 weeks, %</td>
<td>37</td>
<td>47</td>
<td>1.5</td>
</tr>
<tr>
<td>4</td>
<td>Tissue cholesterol uptake, 2 weeks, %</td>
<td>3.8</td>
<td>3.8</td>
<td>0.5</td>
</tr>
</tbody>
</table>

**Treatment with Deuterated Water**

<table>
<thead>
<tr>
<th>Line</th>
<th>Parameter</th>
<th>Serum</th>
<th>Retina</th>
<th>Brain</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Total D&lt;sub&gt;2&lt;/sub&gt;H cholesterol enrichment, 2 weeks, %</td>
<td>16</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td>6</td>
<td>D&lt;sub&gt;2&lt;/sub&gt;H cholesterol enrichment from tissue uptake, 2 weeks, %</td>
<td>0.7</td>
<td>0.5</td>
<td>0.09</td>
</tr>
<tr>
<td>7</td>
<td>Tissue cholesterol biosynthesis, 2 weeks, %</td>
<td>15.3</td>
<td>8.5</td>
<td>12.9</td>
</tr>
</tbody>
</table>

**Summary data**

<table>
<thead>
<tr>
<th>Line</th>
<th>Parameter</th>
<th>Serum</th>
<th>Retina</th>
<th>Brain</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Absolute rate of cholesterol input, μg/day/g wet tissue, (%)</td>
<td>35.7</td>
<td>17.2</td>
<td>116.9</td>
</tr>
<tr>
<td>9</td>
<td>Local biosynthesis, μg/day/g wet tissue (%)</td>
<td>28.2</td>
<td>11.9</td>
<td>112.2</td>
</tr>
<tr>
<td>10</td>
<td>Uptake from blood, μg/day/g wet tissue, (%)</td>
<td>7.5</td>
<td>5.3</td>
<td>4.7</td>
</tr>
<tr>
<td>11</td>
<td>Tissue cholesterol turnover, days</td>
<td>72</td>
<td>113</td>
<td>104</td>
</tr>
</tbody>
</table>

VEH, vehicle-treated mice; SIM, simvastatin-treated mice.
Fig. 1

Lipophilic

[Chemical structures of atorvastatin, 2-hydroxyatorvastatin, simvastatin, and smvastatin hydroxy acid]

Hydrophilic

[Chemical structures of pravastatin (active drug), rosuvastatin (active drug), and n-desmethylosuvastatin (active metabolite)]
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8